Novo Nordisk (NVO, Financial) and Eli Lilly (LLY, Financial) are making headlines again—this time, for potential benefits beyond weight loss. A new study finds that people taking GLP-1 medications like Ozempic, Wegovy, and Mounjaro face up to a 12% lower risk of developing Alzheimer's disease.
Researchers at Washington University in St. Louis examined 215,000 U.S. military veterans with diabetes, comparing those using GLP-1 drugs with those on older treatments. The findings show reduced risks for 42 conditions, including psychotic disorders, seizures, and neurocognitive diseases like Alzheimer's and dementia. However, the study also flags higher risks for kidney issues, pancreatitis, and gastrointestinal conditions among GLP-1 users.
These findings emerge as the Biden administration moves forward with Medicare price negotiations for Ozempic and Wegovy. Meanwhile, Bristol-Myers Squibb (BMY) sees potential in its schizophrenia drug, Cobenfy, as a future Alzheimer's treatment.
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。